Side-by-side comparison of AI visibility scores, market position, and capabilities
New York specialty ingredients (NYSE: IFF) at $11.48B 2024 net sales, EBITDA +16%; flavors/fragrances + N&B health/biosciences ($26B 2021 acquisition), 2025 guidance 1-4% growth competing with Givaudan and dsm-firmenich.
International Flavors & Fragrances Inc. (IFF) is a New York City, New York-based global specialty ingredients company — publicly traded on the New York Stock Exchange (NYSE: IFF) as an S&P 500 Materials component — creating and manufacturing flavors, fragrances, enzymes, probiotics, food ingredients, cosmetic actives, and pharmaceutical excipients for consumer goods companies, food manufacturers, beverage companies, and pharmaceutical firms through approximately 20,000 employees in 110 countries. In fiscal year 2024, IFF reported net sales of $11.48 billion and adjusted operating EBITDA growth of 16% to $2.21 billion, demonstrating improved profitability following the challenging integration of the DuPont Nutrition & Biosciences business (acquired 2021 for ~$26 billion in the largest transaction in IFF's history). For 2025, IFF guided 1-4% comparable currency-neutral sales growth, with continued margin improvement as the integration synergies are realized. CEO Jon Erik Fyrwald leads the company through its integration and portfolio optimization phase. IFF operates across four segments: Nourish (flavors, functional ingredients, proteins, food and beverage innovation), Scent (fine fragrances, consumer fragrances, cosmetic actives), Health & Biosciences (enzymes, microbiome, probiotics, animal nutrition), and Pharma Solutions (pharmaceutical excipients and delivery systems) — serving every major category of consumer products from food and beverages to personal care, household products, and medicine.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.